{"filing":{"accession_number":"0001728117-26-000061","cik":"0001728117","ticker":"GOSS","company_name":"Gossamer Bio, Inc.","form":"8-K","filing_date":"2026-07-14","report_date":null,"primary_document":"goss-20260714.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1728117/000172811726000061/goss-20260714.htm"},"events":[{"id":17974,"run_id":16127,"accession_number":"0001728117-26-000061","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Stockholders approved four material proposals at a Special Meeting: (1) authorization of share issuance upon conversion of $72 million in convertible notes and exercise of 135.8 million warrants; (2) amendment and restatement of the 2019 Incentive Award Plan increasing authorized shares; (3) charter amendment increasing authorized shares from 700 million to 4 billion; and (4) reverse stock split amendments. Vote tallies were disclosed for each proposal.","company_name":"Gossamer Bio, Inc.","ticker":"GOSS","filing_date":"2026-07-14","form":"8-K","submitted_at":null,"items":[{"id":16641,"accession_number":"0001728117-26-000061","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The disclosure centers on stockholder approval of an amendment and restatement of the 2019 Incentive Award Plan, which increases the number of shares authorized for issuance under the plan. This is a compensatory arrangement disclosure under Item 5.02(e), as it involves a material modification to the equity compensation framework available to officers and directors. The plan amendment is material to investors as it affects potential dilution and the scope of equity-based compensation authority.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T10:07:51.583891+00:00","company_name":"","ticker":null,"filing_date":""},{"id":16642,"accession_number":"0001728117-26-000061","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"While Item 5.03 formally discloses a charter amendment increasing authorized shares from 700M to 4B, the substance reveals a dilutive capital event: the amendment was adopted specifically to support conversion of newly issued 7.50% Convertible Senior Secured First Lien Notes due 2030 and exercise of newly issued warrants issued in an Exchange Offer. The 5.7x increase in authorized shares is material and directly tied to dilutive securities issuance, making this a dilutive_issuance event rather than routine governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T10:07:51.583891+00:00","company_name":"","ticker":null,"filing_date":""},{"id":16643,"accession_number":"0001728117-26-000061","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 discloses the results of a Special Meeting of stockholders where four material proposals were voted upon and approved: (1) approval of potential issuance of shares exceeding 20% of outstanding shares upon conversion of $72 million in convertible notes and exercise of 135.8 million warrants; (2) approval of a restated equity plan increasing authorized shares; (3) approval of a charter amendment increasing authorized shares from 700 million to 4 billion; and (4) approval of reverse stock split amendments. The filing presents vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal, which is the standard format for shareholder vote result disclosures under Item 5.07. These approvals are material to investors as they authorize significant dilutive issuances and capital structure changes.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T10:07:51.583891+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16641,"accession_number":"0001728117-26-000061","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The disclosure centers on stockholder approval of an amendment and restatement of the 2019 Incentive Award Plan, which increases the number of shares authorized for issuance under the plan. This is a compensatory arrangement disclosure under Item 5.02(e), as it involves a material modification to the equity compensation framework available to officers and directors. The plan amendment is material to investors as it affects potential dilution and the scope of equity-based compensation authority.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T10:07:51.583891+00:00","company_name":"Gossamer Bio, Inc.","ticker":"GOSS","filing_date":"2026-07-14"},{"id":16642,"accession_number":"0001728117-26-000061","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"While Item 5.03 formally discloses a charter amendment increasing authorized shares from 700M to 4B, the substance reveals a dilutive capital event: the amendment was adopted specifically to support conversion of newly issued 7.50% Convertible Senior Secured First Lien Notes due 2030 and exercise of newly issued warrants issued in an Exchange Offer. The 5.7x increase in authorized shares is material and directly tied to dilutive securities issuance, making this a dilutive_issuance event rather than routine governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T10:07:51.583891+00:00","company_name":"Gossamer Bio, Inc.","ticker":"GOSS","filing_date":"2026-07-14"},{"id":16643,"accession_number":"0001728117-26-000061","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 discloses the results of a Special Meeting of stockholders where four material proposals were voted upon and approved: (1) approval of potential issuance of shares exceeding 20% of outstanding shares upon conversion of $72 million in convertible notes and exercise of 135.8 million warrants; (2) approval of a restated equity plan increasing authorized shares; (3) approval of a charter amendment increasing authorized shares from 700 million to 4 billion; and (4) approval of reverse stock split amendments. The filing presents vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal, which is the standard format for shareholder vote result disclosures under Item 5.07. These approvals are material to investors as they authorize significant dilutive issuances and capital structure changes.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T10:07:51.583891+00:00","company_name":"Gossamer Bio, Inc.","ticker":"GOSS","filing_date":"2026-07-14"}]}